LT
Therapeutic Areas
Lantheus Holdings Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PYLARIFY | Prostate Cancer Imaging | Commercial |
| Definity | Ultrasound Contrast Enhancement | Commercial |
| PNT2002 | Prostate Cancer Imaging | Phase 3 |
| PNT2001 | Metastatic Castration-Resistant Prostate Cancer | Phase 3 |
| LNC1008 | Prostate Cancer (GRPR-targeted) | Phase 1 |
| LNC1010 / LNC1014 | Neuroendocrine Tumors | Phase 1 |
| LNC2001 | Pan-Cancer Imaging (FAP-targeted) | Phase 1 |
| MK-5684 (OTX-2002) | mCRPC | Phase 1/2 |